The relationship between changes in self-reported disability (measured by the Health Assessment Questionnaire - HAQ) in scleroderma and improvement of disease status in clinical practice

被引:0
作者
Lawrence, E. [1 ]
Pope, J. [1 ]
Al Zahraly, Z. [1 ]
Lalani, S. [1 ]
Baron, M. [2 ]
机构
[1] Univ Western Ontario, London, ON, Canada
[2] McGill Univ, Montreal, PQ, Canada
基金
加拿大健康研究院;
关键词
Systemic sclerosis; scleroderma; health assessment questionnaire disability index;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To determine if a low Health Assessment Questionnaire Disability Index (HAQ-DI) score predicts subsequent improvement over the next one to two years in clinical practice and if a low HAQ is predictive of improvement in early, late, diffuse and limited SSc subsets. Methods. HAQs collected at one site annually were used to determine serial relationships in low baseline HAQ and improvement in overall status over the following one to two years. Data were divided into early (53 years) and late, and then further into limited and diffuse SSc subgroups. We verified our results in the Canadian Scleroderma Research Group (CSRG) database. Results. 120 SSc patients had a baseline HAQ-DI of 0.97+/-0.07 (SEM). Low HAQs predicted improvement in overall HAQ at one and two years, but was not statistically significant in predicting physician improvement rating. However, improving HAQs were associated with improvement in physician assessment (better vs. same vs. worse) for overall SSc (p=0.005), early diffuse SSc (p=0.008), overall limited SSc (p=0.02) and late limited SSc (p=0.03) at I year (but not at 2 years). The relationship was similar for severity of disease where changes in damage were related to changes in HAQ only over the first year for all 4 subgroups. Conclusion. The HAQ is a useful 'marker' of change in status in clinical practice, where an improved HAQ is associated with improved physician global assessment. The relationship is only helpful for an interval of one year. Low HAQ did not predict subsequent improvement by physician rating in SSc patients.
引用
收藏
页码:S32 / S37
页数:6
相关论文
共 15 条
  • [1] PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA)
    不详
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (05): : 581 - 590
  • [2] CLEMENTS P, 1995, J RHEUMATOL, V22, P1281
  • [3] Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis
    Clements, P. J.
    Roth, M. D.
    Elashoff, R.
    Tashkin, D. P.
    Goldin, J.
    Silver, R. M.
    Sterz, M.
    Seibold, J. R.
    Schraufnagel, D.
    Simms, R. W.
    Bolster, M.
    Wise, R. A.
    Steen, V.
    Mayes, M. D.
    Connelly, K.
    Metersky, M.
    Furst, D. E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (12) : 1641 - 1647
  • [4] MEASUREMENT OF PATIENT OUTCOME IN ARTHRITIS
    FRIES, JF
    SPITZ, P
    KRAINES, RG
    HOLMAN, HR
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (02): : 137 - 145
  • [5] Giorgetti F, 2004, Reumatismo, V56, P51
  • [6] Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review
    Henness, Sheridan
    Wigley, Fredrick M.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2007, 19 (06) : 611 - 618
  • [7] Update on indices of disease activity in systemic sclerosis
    Hudson, Marie
    Steele, Russell
    Scleroderma, Canadian
    Baron, Murray
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2007, 37 (02) : 93 - 98
  • [8] LeRoy EC, 2001, J RHEUMATOL, V28, P1573
  • [9] Pope JE, 2001, ARTHRITIS RHEUM-US, V44, P1351, DOI 10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO
  • [10] 2-I